News
The approval was based on data from the phase 3 ACTT-2 and COV-BARRIER studies.
News
Investigators report findings from a secondary analysis of the DARE-19 trial, which compared dapagliflozin with placebo in patients hospitalized with COVID-19.
News
No significant difference seen in five-, 10-day course for severe COVID-19 without mechanical ventilation.